REGN7257 in Adult Patients With Severe Aplastic Anemia That Is Refractory to or Relapsed on Immunosuppressive Therapy
Terminated · Phase 1 · NCT04409080
Conditions: Severe Aplastic Anemia (SAA)
At a glance
- Research payments reported, 2025
- $69,866
- U.S. investigators named
- 2
- Sites paid
- 2
- Planned or actual enrollment
- 17
About the trial
- Sponsor
- Regeneron Pharmaceuticals
- Tested
- REGN7257 (drug)
- Dates
- Started 2021-01-13; completion 2024-10-17
- Results posted
- Not yet
This study is researching an experimental drug called REGN7257 (called "study drug"). The study is focused on patients who have severe aplastic anemia (SAA), a disease of the bone marrow resulting in an impairment of the production of blood cells. The main purpose of this two-part study (Part A and Part B) is to test how safe and tolerable REGN7257 is in patients with SAA in which other Immunosuppressive therapies (ISTs) have not worked well. The study is looking at several other research questions to better understand the following properties of REGN7257: * Side effects that may be experienced by participants taking REGN7257 * How REGN7257 works in the body * How much REGN7257 is present…
From ClinicalTrials.gov, last updated 2026-06-22. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Regeneron Pharmaceuticals, Inc. reported $69,866 in research payments for this study in 2025 (8 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Sophia R. Balderman, MD Hematology · Cleveland, OH
- Tapan M. Kadia, M.D. Internal Medicine · Houston, TX
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Ut MD Anderson Cancer Center $41,814
- Cleveland Clinic, OH $28,052
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.